FDA Approves Treg Cell Therapy - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

  • By

  • Kathryn Wighton

  • July 1, 2026

  • 2 min

Share

Original Source(s)

FDA Approves Treg Cell Therapy

  • by Kathryn Wighton

  • July 1, 2026

Related Content

Emergency diagnosis may flag poor outcomes beyond cancer

Across 13 noncancer conditions, emergency diagnosis was common and associated with higher 1-year mortality.

FDA expands essential thrombocythemia care

Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.

FDA approves first therapy for warm autoimmune hemolytic anemia

The phase 2/3 ENERGY trial evaluated durable hemoglobin response with nipocalimab vs placebo in adults with warm autoimmune hemolytic anemia.